title: Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
abstract: BACKGROUND
  Mirabegron, the first β3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms. Because β3-adrenoceptors are expressed in cardiovascular (CV) tissues, there are concerns that OAB treatment with β3-adrenoceptor agonists may affect the heart and vasculature.
  
  
  OBJECTIVE
  To provide a summary of CV effects of β3-adrenoceptor agonists in clinical studies.
  
  
  METHODS
  A systematic literature search from inception until November 2014 was performed on studies in PubMed and Medline.
  
  
  RESULTS
  Twenty papers, published between 1994 and 2014, were identified: mirabegron (16), solabegron (2), AK-677 (1), and BRL35135 (1). More detailed CV data from mirabegron studies were available in online regulatory documents filed with the US Food and Drug Administration and the UK National Institute for Health and Care Excellence.
  
  
  CONCLUSIONS
  The CV safety of mirabegron appears to be acceptable at therapeutic doses and comparable with that of antimuscarinic agents, currently first-line therapy for OAB.
  
  
  RESULTS
  In this review we looked at the cardiovascular (CV) effects of β3-adrenoceptor agonists used for the treatment of overactive bladder (OAB). The CV safety of mirabegron (the only clinically approved β3-adrenoceptor agonist) appears to be acceptable at therapeutic doses and comparable with that of antimuscarinic agents, the current first-line therapy for OAB.
authors.affiliation: IRCCS AOU San Martino - University of Genoa, Genoa, Italy.
authors.forename: Gian Marco
authors.initials: GM
authors.lastname: Rosa
authors.affiliation: IRCCS AOU San Martino - University of Genoa, Genoa, Italy.
authors.forename: Simone
authors.initials: S
authors.lastname: Ferrero
authors.affiliation: Department of Urology, NYU Langone Medical Center, New York, NY, USA.
authors.forename: Victor W
authors.initials: VW
authors.lastname: Nitti
authors.affiliation: Division of Geriatric Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Adrian
authors.initials: A
authors.lastname: Wagg
authors.affiliation: Astellas Pharma Europe Ltd, Chertsey, Surrey, UK.
authors.forename: Tahir
authors.initials: T
authors.lastname: Saleem
authors.affiliation: Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. Electronic address: c.r.chapple@shef.ac.uk.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Chapple
mesh_terms: D000083:Acetanilides / Q000009:adverse effects*; D058667:Adrenergic beta-3 Receptor Agonists / Q000009:adverse effects*; D000814:Aniline Compounds / Q000009:adverse effects; D001565:Benzoates / Q000009:adverse effects; D001713:Biphenyl Compounds / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D004562:Electrocardiography / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D013844:Thiazoles / Q000009:adverse effects*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D000814:Aniline Compounds; D001565:Benzoates; D001713:Biphenyl Compounds; D013844:Thiazoles; C523977:solabegron; C520025:mirabegron
keywords: Cardiovascular; Overactive bladder; Safety; β3-Adrenoceptor agonist